{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-24-000199","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.293711+00:00","generated_at":"2026-05-31T07:19:45.447007+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurocrine's NBI-1117568 meets Phase 2 primary endpoint; 7.5-point PANSS reduction vs placebo","bullets":["20 mg once-daily dose met primary endpoint: placebo-adjusted PANSS reduction of 7.5 points (p=0.011, effect size 0.61) at Week 6.","Dose also statistically significant on CGI-S, Marder positive and negative symptom scores.","NBI-’568 well tolerated; no weight gain vs placebo; GI events low; discontinuation rates similar to placebo.","Company plans to advance NBI-’568 into Phase 3 development in schizophrenia in early 2025.","Other doses (40 mg, 60 mg QD, 30 mg BID) did not reach statistical significance on primary endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-24-000199","json":"https://secwatch.observer/filing/0000914475-24-000199.json","markdown":"https://secwatch.observer/filing/0000914475-24-000199.md","text":"https://secwatch.observer/filing/0000914475-24-000199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000199/0000914475-24-000199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447524000199/nbix-20240828.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:19:45.447007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}